Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
63 miljoen aandelen short 3 miljoen meer.
er is iets gaande ??? voorbeurs + 22% momenteel !!!!!!
If you go to J&J website you can view PowerPoints for today's conference call. Clearly shows that Imetelstat remains in the J&J pipeline for 2021 and beyond.
Bij Binck (waar de US koersen na sluit Europa niet meer worden bijgewerkt) staat het aandeel NU op -9%. Bij Webul op 5,5 is -7% Hoe zit dat ?
H.D.L. schreef op 13 september 2018 18:49 :
Bij Binck (waar de US koersen na sluit Europa niet meer worden bijgewerkt) staat het aandeel NU op -9%.
Bij Webul op 5,5 is -7%
Hoe zit dat ?
Hier zie je de realtime koers van Geron:finance.yahoo.com/quote/GERN/?p=GERN
Wordt weer 2 weken wachten voor opt in of opt out pffff
hartelijk dank @ sjonnie2
Morgen hopelijk groot nieuws CD of een Buy Out wie weet.......
zwabbertje schreef op 13 september 2018 19:35 :
Wordt weer 2 weken wachten voor opt in of opt out pffff
Als ze maar doorgaan met de samenwerking, maar daar lijkt het wel op uit te komen gezien de verwijzingen naar de het programma van Geron in de presentatie van 13 sept jl. Daarnaast waren die vacatures ook al een teken aan de wand wat mij betreft, dus ieder laag koersniveau is voor mij reden om wat uit te breiden de komende weken. Ik had uberhaupt niet verwacht dat we nu uitsluitsel zouden hebben, de koers zal de komende weken nog wel flink schommelen!
Kyle Dennis might be the world’s best biotech trader under 30 years old. He’s turned a $15k grubstake into over $4.1 MILLION in profits. Now, you can learn directly from Kyle and see what trades he is making in this limited-time opportunity. Learn how his “Sniper Trades” can take your trading to levels you never thought possible! It’s going to be an important week for Geron Corporation (NASDAQ:GERN). As a brief recap of what is quickly becoming perhaps the most interesting drama of 2018 in the biotech sector, GERN shares have been running higher over the past few weeks as the company approaches the decision point for whether or not Johnson and Johnson (NYSE:JNJ) will continue forward with the imetelstat development partnership with Geron. The consequences, as we have noted, are defining for GERN shareholders: JNJ has deep pockets and can help GERN advance the drug, and GERN is in line for a major milestone payment that will be aborted if the relationship is truncated at this stage. If the relationship moves forward, GERN will likely carry far less in the way of dilution risk in the equation for bringing imetelstat to market. The outcome will also be a defining marker in determining the market’s understanding of the eventual value of imetelstat as a marketable treatment. Finally, there isn’t much else going on at Geron besides imetelstat. So, the chips are all on the table here. Geron Corporation (NASDAQ:GERN), for a little perspective, earns a current market cap value of $1B as a biopharmaceutical company with a principal focus on becoming the first to move telomerase inhibitor treatments to market for blood cancers. The company has a significant war chest ($19.4M) of cash and cash equivalent securities on the books according to its most recent 10-Q filing, with about $141M in additional marketable securities. That compares with about $4.9M in total current liabilities. In addition, GERN is pulling in trailing 12-month revenues of $880K on sturdy top-line growth, with y/y quarterly revenues growing at 19.5%. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company currently is running two key studies. IMerge is a two-part clinical trial evaluating imetelstat in transfusion dependent patients with Low or Intermediate-1 risk myelodysplastic syndromes (MDS) who have relapsed after or are refractory to prior treatment with an erythropoiesis stimulating agent, or ESA. The primary efficacy endpoint is the rate of red blood cell transfusion independence lasting at least 8 weeks. Part 1 is a Phase 2, open-label, single-arm trial of imetelstat, and Part 2 is designed to be a Phase 3, randomized, controlled trial. Part 2 has not yet begun. IMbark is a Phase 2 trial in patients with Intermediate-2 or High-Risk myelofibrosis (MF) who have relapsed after or are refractory to prior treatment with a JAK inhibitor. In March 2018, Janssen officially closed the trial to new patient enrollment. In the second quarter of 2018, Janssen initiated a protocol-specified primary analysis of IMbark, which includes an assessment of overall survival. The Company expects that following completion of the protocol-specified primary analysis, Janssen will notify Geron whether it elects to maintain the license rights and continue the development of imetelstat in any indication (the Continuation Decision). Geron expects Janssen to inform the Company of its decision by the end of the third quarter of 2018, as noted above. Behind the Scenes As noted above, this week is likely to frame the action in front of the all-important JNJ decision. Last week, JNJ teased the issue further by including the suggestion of a 2019-2021 potential filing with the FDA in an important drug development program update and conference call. But the company then said it was still up for grabs. Our own perspective, as noted in our last piece focused on the game theory in play, is that JNJ management would be far less cavalier about dropping these hints if it were leaning toward cutting off the relationship. In addition, one cannot dismiss the idea that the context for this game theory landscape is part of a negotiation going on right now behind closed doors. If JNJ were perhaps in early-stage negotiations with GERN about a possible acquisition, then proving to Geron management how important JNJ’s involvement in the development program might be a strategy in play. In any case, it will be important for traders to avoid getting caught up in the hour-to-hour oscillations of the stock, especially in reaction to rumors and unsubstantiated stories passing for news in front of the actual announcement. We will update the story again soon as developments transpire.
MVo_ schreef op 17 september 2018 13:05 :
[...]
Als ze maar doorgaan met de samenwerking, maar daar lijkt het wel op uit te komen gezien de verwijzingen naar de het programma van Geron in de presentatie van 13 sept jl.
Daarnaast waren die vacatures ook al een teken aan de wand wat mij betreft, dus ieder laag koersniveau is voor mij reden om wat uit te breiden de komende weken. Ik had uberhaupt niet verwacht dat we nu uitsluitsel zouden hebben, de koers zal de komende weken nog wel flink schommelen!
Alles wijst erop dat ze doorgaan of wel.een overname Anders zou het allang bekend zijn geweest . De koers hebben ze aardig in bedwang gehouden de afgelopen dagen en dat schijnt alles met de opties temaken hebben die gisteren zijn verlopen.
Geron: The Last Chapter Sep. 21, 2018 5:11 AM•GERN Summary Geron has waited 975 market days for its Johnson & Johnson imetelstat answer. The company has ~1 week to go before it will know whether or not it is flying solo. Those interested in a hot trade should pay attention. A continuation decision and then later a buyout are the endgame for optimistic Geron investors. Geron (NASDAQ:GERN) has one therapy, imetelstat, currently in clinical trials for treatment of two serious hematological cancers. The first trial is IMbark for Myelofibrosis (MF), the second is IMerge for Myelodysplastic Syndrome (MDS). There are indications that a third trial for AML is the likely next candidate. In fact, imetelstat has been in a variety of clinical trials over the past decade and more. Geron bulls argue that as researchers achieve a better understanding of the workings of imetelstat, an entire imetelstat ecosystem may sprout. I have established Geron as the top holding in my speculative biotech portfolio. I have been watching its movements carefully expecting an imminent visit to $10 by 10/10. Where it goes from there will be heavily data-dependent, as I will discuss.
We zijn de nieuwe week alvast weer goed begonnen ! +7%
+13%, lekker dagje! Het einde van september komt steeds dichterbij
Iemand die meer info kan geven over aanstaande belangrijke gebeurtenissen voor GERON?
F U MONEY schreef op 25 september 2018 10:30 :
Iemand die meer info kan geven over aanstaande belangrijke gebeurtenissen voor GERON?
Jazeker, lees bijgevoegde link maar even goed door.finance.yahoo.com/news/why-geron-corp...
Bedankt voor de link. "Fortunately, bulls and bears alike don't have long to wait to find out J&J's final decision. Although this long-awaited continuation decision is expected no later than the end of this month, J&J is more likely than not to make an announcement before the end of this week. Clinical and regulatory updates of any kind, after all, are rarely announced over the weekend. " Nu is het een kwestie van aftellen :-)
Geron: How To Play The Imetelstat Catalyst Sep. 26, 2018 9:30 AM ET | About: Geron Corporation (GERN), Includes: JNJ Jonathan Weber Jonathan Weber Value, dividend investing, Growth, growth at reasonable price (10,521 followers) Summary Imetelstat looks promising and targets indications with sizeable markets. Geron could earn significant amounts of money with Imetelstat if everything goes the right way. Geron could self-fund for a while, the balance sheet looks relatively strong. Thesis Geron's (GERN) Imetelstat is being evaluated for several indications right now. Johnson & Johnson's (JNJ) Janssen will have to make a decision on whether to continue with its collaboration agreement, and that decision will come during the next couple of days. A continuation seems likely based on several clues, but even without Janssen as a collaboration partner, Geron's Imetelstat would have some value. A look at Geron's financials shows that the company would be able to finance its operations for several years, and Imetelstat's results during clinical studies look promising. Due to the high volatility of Geron's shares option premiums are quite high, which gives investors the opportunity to employ options strategies instead of, or in addition to, going long the stock. Imetelstat Is A Valuable Asset Imetelstat is a thio-phosphoramidate oligonucleotide which has an added lipid group for better cell permeability. Imetelstat can inhibit telomerase activity, trials have also proven that Imetelstat can shorten telomeres. In pre-clinical trials, Imetelstat has impacted the growth of primary tumors and reduced metastases, over a wide variety of tumor types, including solid tumors and hematologic tumors. These promising results during pre-clinical testing caused Geron to test the component in clinical trials as well. Imetelstat was, among other indications, tested in non-small cell lung cancer (NSCLC) as maintenance therapy, and in metastatic breast cancer (in combination with paclitaxel). The most promising results, though, came from the trials for hematologic cancers.
D DAY vanmiddag om 2 uur het is alles of niets. Persconferentie...........
zwabbertje schreef op 27 september 2018 07:02 :
D DAY vanmiddag om 2 uur het is alles of niets.
Persconferentie...........
Weet niet of er al wat uitgelekt is maar er staat nu voor beurs een koers van $ 1,90 dus het wordt denk ik helemaal niets!!!! Gelukkig geen positie op het moment, hoop meer niet hier
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
881,78
+0,30%
EUR/USD
1,0789
-0,22%
FTSE 100
7.952,62
+0,26%
Germany40^
18.505,40
+0,15%
Gold spot
2.234,24
+1,92%
NY-Nasdaq Composite
16.399,52
+0,51%
Stijgers
Dalers